Skip to content

To compare the clinical effect of traditional Chinese medicine fumigation and compression therapy in the prevention of chemotherapy-induced peripheral neuropathy

To compare the clinical effect of traditional Chinese medicine fumigation and compression therapy in the prevention of chemotherapy-induced peripheral neuropathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077008
Enrollment
Unknown
Registered
2023-10-26
Start date
2023-10-31
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Control group:The control group was given routine nursing measures, including: ? patients were told to keep warm and avoid contact with cold objects, metal products, cold air, etc.
? Light diet, avoid spicy stimulation
? Reduce the skin friction of the limbs, and do not apply irritating liquids and ointments.
Chinese medicine fumigation group:In the traditional Chinese medicine fumigation group, on the basis of the treatment of the control group, Huangqi Guizhi Wuwu decoction was added, provided by the Chi
Compression therapy group:The compression therapy group was treated with compression therapy on the basis of the treatment of the control group. According to previous studies [4], on the day of each c

Sponsors

Jiangsu Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Colorectal cancer patients diagnosed as malignant tumor by pathology and scheduled to receive oxaliplatin intravenous chemotherapy; (2) aged 18-75 years old; (3) KPS score =60; (4) the expected survival time is more than 3 months; (5) understand and agree to receive the treatment, and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) previous diseases that may have caused peripheral neuropathy (such as severe cervical spondylosis or postherpetic neuralgia);(2) inability to tolerate heat stimulation, skin disease or edema of limbs, or allergy to herbal ingredients;(3) severe cardiovascular and cerebrovascular diseases, liver and kidney insufficiency;(4) pregnant and lactating women;(5) patients receiving other neuroprotective drugs other than those used in the trial;(6) patients with cognitive impairment or mental illness.

Design outcomes

Primary

MeasureTime frame
Incidence of peripheral neuropathy;

Secondary

MeasureTime frame
Severity of symptoms of peripheral neuropathy;quality of life;TCM syndrome score;

Countries

China

Contacts

Public ContactZhang Xiaotao

Nanjing University of Chinese Medicine,School of Nursing;Jiangsu Province Hospital of Chinese Medicine,Department of Nursing, Affiliated Hospital of Nanjing University of Chinese Medicine

20211014@njucm.edu.cn+86 159 5197 9945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026